ACCD vs. RAMP, ASTH, UPWK, EVTC, APLD, GDRX, SEZL, DFIN, XMTR, and NEO
Should you be buying Accolade stock or one of its competitors? The main competitors of Accolade include LiveRamp (RAMP), Astrana Health (ASTH), Upwork (UPWK), EVERTEC (EVTC), Applied Digital (APLD), GoodRx (GDRX), Sezzle (SEZL), Donnelley Financial Solutions (DFIN), Xometry (XMTR), and NeoGenomics (NEO). These companies are all part of the "business services" industry.
Accolade vs.
LiveRamp (NYSE:RAMP) and Accolade (NASDAQ:ACCD) are both business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
LiveRamp has higher revenue and earnings than Accolade. Accolade is trading at a lower price-to-earnings ratio than LiveRamp, indicating that it is currently the more affordable of the two stocks.
LiveRamp has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Accolade has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500.
93.8% of LiveRamp shares are held by institutional investors. Comparatively, 85.0% of Accolade shares are held by institutional investors. 3.4% of LiveRamp shares are held by company insiders. Comparatively, 8.2% of Accolade shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, LiveRamp had 6 more articles in the media than Accolade. MarketBeat recorded 9 mentions for LiveRamp and 3 mentions for Accolade. LiveRamp's average media sentiment score of 0.96 beat Accolade's score of 0.41 indicating that LiveRamp is being referred to more favorably in the media.
LiveRamp has a net margin of 0.01% compared to Accolade's net margin of -40.36%. LiveRamp's return on equity of 0.97% beat Accolade's return on equity.
LiveRamp presently has a consensus target price of $39.33, indicating a potential upside of 25.87%. Accolade has a consensus target price of $7.46, indicating a potential upside of 7.59%. Given LiveRamp's stronger consensus rating and higher probable upside, equities research analysts clearly believe LiveRamp is more favorable than Accolade.
LiveRamp received 67 more outperform votes than Accolade when rated by MarketBeat users. Likewise, 70.12% of users gave LiveRamp an outperform vote while only 55.43% of users gave Accolade an outperform vote.
Summary
LiveRamp beats Accolade on 16 of the 18 factors compared between the two stocks.
Get Accolade News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACCD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Accolade Competitors List
Related Companies and Tools
This page (NASDAQ:ACCD) was last updated on 2/22/2025 by MarketBeat.com Staff
